← All trials
NCT04563299
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 8, 2020
- Primary completion
- Sep 1, 2021
- Completion date
- Nov 1, 2021
- First posted
- Sep 24, 2020
- Last posted
- Sep 24, 2020
- Enrollment
- 40
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Retina Vitreous Associates of FloridaLead sponsor
- Ocular Therapeutix, Inc.Collaborator
- Retina Vitreous Associates of FloridaOverall official - principal investigator
- Retina Vitreous Associates of FloridaReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.